Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases

BACKGROUND: High-dose intravenous immune globulins (IVIg) are frequently used in refractory juvenile dermatomyositis (JDM) but are often poorly tolerated. High-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins (fSCIg) allow the administration of much higher doses of immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Speth, Fabian, Haas, Johannes-Peter, Hinze, Claas H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022227/
https://www.ncbi.nlm.nih.gov/pubmed/27623619
http://dx.doi.org/10.1186/s12969-016-0112-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5022227/
https://www.ncbi.nlm.nih.gov/pubmed/27623619
http://dx.doi.org/10.1186/s12969-016-0112-6

Ejemplares similares